HGPS is an exceptionally rare genetic disorder characterized by accelerated features of aging, including growth failure, loss of subcutaneous fat, stiff joints, vascular disease and severe cardiovascular complications. Most cases are caused by a mutation in the LMNA gene, which encodes the nuclear structural proteins lamins A and C. The mutation creates an abnormal form of lamin A known as progerin. Because progerin retains a chemical modification that normally would be removed during protein maturation, it remains abnormally attached to the inner nuclear membrane. Over time, progerin distorts the nucleus, weakens its mechanical properties and interferes with essential processes such as DNA repair, replication and gene regulation.

The new work focuses on chromatin, the dynamic complex of DNA and proteins that packages the genome inside the nucleus. Chromatin is not arranged randomly: tightly packed regions, known as heterochromatin, generally restrict gene activity, while more open regions allow transcriptional machinery to access DNA. This organization must be constantly adjusted as cells respond to stress, divide or adopt specialized identities. In HGPS, progerin-associated nuclear damage has been linked to the loss or redistribution of heterochromatin. Such changes can expose genes at the wrong time, silence genes that cells need, and undermine the stable patterns of gene expression required for long-term cellular health.

HMGA1 and HP1β operate at different but complementary points in this process. HMGA1 is a small, non-histone chromatin protein that binds DNA and changes its shape, helping assemble larger regulatory complexes. It can influence transcription, DNA repair and the formation of specialized chromatin domains. HP1β, encoded by the CBX1 gene, is a member of the heterochromatin protein 1 family. These proteins recognize methylated histones, chemical tags on chromatin-associated proteins that are commonly associated with gene silencing and compact genome organization. HP1β can act as a molecular adaptor, helping recruit additional factors and stabilize regions of condensed chromatin.

According to the study, the relationship between HMGA1 and HP1β becomes disturbed in HGPS cells, contributing to abnormal chromatin remodeling and premature cellular aging. The significance of the finding lies in the idea that HMGA1 is not functioning in isolation. Instead, its activity appears to be connected to HP1β-dependent chromatin organization, creating an axis that can influence the physical structure of the genome and the transcriptional programs that preserve cellular identity. When this regulatory relationship is disrupted, cells may lose the ability to maintain normal heterochromatin, activate stress responses inappropriately and enter a senescent state, in which they remain alive but divide poorly and release inflammatory signals.

This proposed mechanism helps clarify why HGPS affects many tissues even though the initiating mutation is present in a single gene. The nuclear envelope is mechanically connected to chromatin, and chromatin is chemically connected to gene expression. A structural defect caused by progerin can therefore propagate inward, altering the placement and accessibility of genomic regions. If HMGA1 and HP1β fail to coordinate the response, the resulting changes may affect genes involved in proliferation, metabolism, DNA damage responses and inflammation. The effect is not simply a damaged nucleus or a collection of isolated gene-expression errors; it is a self-reinforcing breakdown in the systems that organize and protect the genome.

The researchers’ focus on an axis rather than a single protein is also important for potential treatment strategies. HGPS has no cure, although therapies such as farnesyltransferase inhibition can reduce some consequences of progerin processing and may improve outcomes for certain patients. However, correcting the abnormal lamin protein does not necessarily restore every layer of nuclear regulation. A therapy aimed at chromatin remodeling could, in principle, address downstream effects that remain after the primary structural defect has been reduced. Modulating HMGA1 activity, stabilizing HP1β-associated heterochromatin or restoring appropriate chromatin marks could represent future approaches, although such interventions would require exceptional precision because these proteins regulate fundamental processes in healthy cells.

The findings may also resonate beyond progeria. Several molecular features observed in HGPS—including heterochromatin loss, persistent DNA damage and cellular senescence—are also associated with ordinary aging and age-related disease. Progeria is often described as a “fast-forward” model of aging, but it is not simply normal aging at an accelerated pace. The disorder has a distinct genetic cause and produces unique pathological effects. Even so, studying its molecular circuitry can reveal how nuclear architecture, epigenetic regulation and cellular stress interact over time. The HMGA1–HP1β connection could therefore provide a framework for investigating whether similar chromatin failures contribute to vascular aging, tissue degeneration or chronic inflammation in the general population.

The research also underscores the importance of looking beyond DNA sequence when studying genetic disease. The mutation in LMNA supplies the initiating instruction, but its consequences unfold through protein processing, nuclear mechanics, chromatin chemistry and gene regulation. Epigenetic systems such as histone modification and chromatin compaction do not change the underlying genetic code; instead, they determine how that code is interpreted. In HGPS, the HMGA1–HP1β axis appears to be one of the regulatory circuits translating nuclear damage into altered genome behavior. Understanding that translation may help scientists identify biomarkers that reveal disease progression earlier and determine which cellular pathways are most responsive to treatment.

The study does not turn HGPS into a solved problem, and additional work will be needed to establish how the HMGA1–HP1β axis behaves across different cell types, tissues and stages of disease. Researchers must also determine whether restoring the pathway can reverse established cellular damage or mainly prevent further decline. Nevertheless, the work adds a crucial layer to the progeria story: premature aging may arise not only because progerin deforms the nucleus, but because that deformation disrupts the molecular partnerships that keep chromatin organized. By exposing this link, the study brings scientists closer to understanding how the genome loses its structural discipline—and how that failure might eventually be repaired.

Subject of Research: The role of the HMGA1–HP1β chromatin-regulatory axis in premature aging associated with Hutchinson–Gilford progeria syndrome.

Article Title: HMGA1-HP1β axis regulates premature aging in Hutchinson-Gilford progeria syndrome through chromatin remodeling.

Article References: Hu, Q., Sun, Q., Xiang, W. et al. “HMGA1-HP1β axis regulates premature aging in Hutchinson-Gilford progeria syndrome through chromatin remodeling.” Nature Communications (2026). https://doi.org/10.1038/s41467-026-76789-6

Image Credits: AI Generated

DOI: 10.1038/s41467-026-76789-6

Keywords: Hutchinson–Gilford progeria syndrome, premature aging, HMGA1, HP1β, chromatin remodeling, heterochromatin, progerin, nuclear architecture, cellular senescence, epigenetics

Progeria, a fatal genetic disease, is caused by a mutation in the LMNA gene leading to the production of progerin, a toxic protein that disrupts the structural integrity of the nuclear envelope in cells. This disruption accelerates cellular aging, particularly affecting cardiovascular tissues and rapidly inducing heart-related complications which are the primary cause of death in affected children, often by their mid-teens. Despite its rarity, the aggressive nature and lack of effective treatments for HGPS have driven urgent research efforts worldwide.

Until now, the FDA-approved treatment for progeria has been lonafarnib, a farnesyltransferase inhibitor designed to reduce the accumulation of progerin. Though this drug has extended life expectancy to some degree, it neither reverses the underlying generative damage nor significantly improves heart function. The Bristol and IRCCS MultiMedica team, led by Dr. Yan Qiu, Professor Paolo Madeddu, and Professor Annibale Puca, sought to pivot from this paradigm by exploring protective genetic factors that help sustain cardiovascular health in extreme old age.

Central to their approach is the LAV-BPIFB4 gene, a variant enriched in long-living individuals, which previous studies have demonstrated enhances vascular function and resilience to age-related endothelial decline. The researchers hypothesized that this gene could counteract the deleterious effects of progerin without targeting the toxic protein directly, instead reinforcing the tissues’ capacity to manage cellular stress and maintain homeostasis.

Using a well-established mouse model genetically engineered to express the progerin mutation, the team administered a single injection of the LAV-BPIFB4 gene. The results were remarkable: treated mice exhibited significant improvement in diastolic function, a measure of the heart’s ability to relax and fill properly. Moreover, histological analyses revealed reduced fibrosis in cardiac tissues, indicating less damage and scarring. Enhanced angiogenesis was observed as well, with an increase in the formation of small blood vessels crucial for nutrient delivery and tissue repair.

Extending their findings to human biology, the researchers tested the longevity gene’s effects on cellular samples from progeria patients. They found that cells expressing LAV-BPIFB4 showed markedly diminished aging markers and decreased fibrotic activity. Intriguingly, this protective influence occurred without altering progerin levels directly, suggesting the gene enhances cellular defense mechanisms rather than eliminating the toxic protein.

This strategy marks a significant departure from previous therapies which focused solely on reducing progerin accumulation. By shifting the focus towards enhancing the body’s intrinsic ability to tolerate and combat progerin-induced stress, the work opens new therapeutic possibilities not only for Progeria but potentially for broader cardiovascular aging and age-related diseases. It reflects an emerging paradigm in gerontology and regenerative medicine that emphasizes the modulation of longevity pathways.

Professor Annibale Puca highlighted the translational potential of the work, envisioning future clinical applications involving gene therapy or advanced delivery systems such as protein- or RNA-based platforms. This flexibility could allow personalized and more effective interventions aimed at improving the quality of life and survival of children afflicted by this relentless disease.

Beyond the immediate clinical implications for HGPS, the discovery adds compelling evidence to the role of longevity genes in cardiovascular health. It suggests that the genetic secrets held by supercentenarians could inform treatments that promote healthy aging in the general population, mitigating cardiac decline inherent in the natural aging process. This convergence of rare disease research and aging science exemplifies the potential for cross-disciplinary breakthroughs.

The study, published in the prestigious journal Signal Transduction and Targeted Therapy, represents the first demonstration that a longevity-associated gene can prevent diastolic dysfunction in a progeria animal model. It sets a new benchmark for the development of therapies that harness natural protective mechanisms against age-related cardiovascular deterioration and genetic disorders marked by premature aging.

Researchers continue to investigate how LAV-BPIFB4 modulates immune responses and cardiovascular integrity under pathological stress. The ongoing studies aim to delineate the molecular pathways involved and optimize gene delivery methodologies to maximize therapeutic efficacy and safety. Given the complexity of progeria and the delicate nature of pediatric interventions, such comprehensive preclinical evaluation is essential before moving to human trials.

In sum, this innovative research breathes new life into the fight against progeria, offering hope to patients and families affected by the disease. It also underscores the broader potential of longevity genes to revolutionize how medicine approaches aging and cardiovascular disease, providing a beacon for future research and therapeutic innovation.

Subject of Research: Animals

Article Title: LETTER OPEN A longevity-associated variant of the human BPIFB4 gene prevents diastolic dysfunction in progeria mice

News Publication Date: 16-Oct-2025

Web References:
Signal Transduction and Targeted Therapy Journal
DOI: 10.1038/s41392-025-02416-3

Keywords: Progeria, Genetic disorders, Health and medicine, Children

HGPS is a rare genetic disorder caused by mutations in the LMNA gene, resulting in the production of progerin, an abnormal lamin A protein that compromises nuclear structural integrity. Beyond the well-documented cardiovascular deterioration and musculoskeletal impairments, HGPS patients experience marked lipodystrophy—the pathological loss of subcutaneous fat—leading to severe metabolic complications. The mechanisms connecting progerin accumulation to defective adipogenesis, however, have remained obscure, hindering therapeutic development. The current research addresses this gap by profiling miRNA expression patterns associated with adipocyte differentiation deficits in HGPS.

Employing fibroblast-derived induced pluripotent stem cells (iPSCs) from both HGPS patients and healthy controls, the researchers differentiated these stem cells into adipocytes and carefully analyzed miRNA activity at multiple stages of cell maturation. The results showcased a striking overexpression of miR-145-5p and miR-27b-3p in HGPS cells, correlating strongly with impaired adipogenic differentiation. These microRNAs were found to post-transcriptionally suppress key adipogenic transcription factors and markers, disrupting the tightly orchestrated gene regulatory networks required for the development of functional fat cells.

Further experiments confirmed that antagonizing miR-145-5p and miR-27b-3p via targeted inhibitors led to significant restoration of adipogenesis in HGPS-derived cells. This reversal was evidenced by increased expression of adipogenic markers such as PPARγ and FABP4, alongside improved lipid droplet accumulation. These findings not only establish a causative role for these microRNAs in the adipocyte maturation block but also spotlight them as promising molecular targets for therapeutic intervention aimed at mitigating lipodystrophy in premature aging.

The study also extended its findings in vivo, utilizing mouse models engineered to express progerin. Similar to human HGPS cells, adipose tissue from these mice exhibited elevated levels of miR-145-5p and miR-27b-3p concomitant with impaired fat deposition and metabolic dysfunction. This cross-species validation enhances the translational significance of the work and sets a robust foundation for future drug development targeting microRNA pathways to restore healthy adipose tissue architecture in HGPS.

By elucidating the interplay between aberrant microRNA expression and disrupted fat cell formation, the researchers shed light on a critical aspect of HGPS pathology that has eluded comprehensive understanding. The study broadens the therapeutic landscape beyond traditional approaches focused on managing cardiovascular and skeletal effects, redirecting efforts toward rectifying adipose tissue deficits that significantly impact patients’ quality of life and metabolic health.

Moreover, the implications of this research transcend HGPS, informing broader biomedical contexts involving adipose tissue dysfunction such as obesity, type 2 diabetes, and other metabolic syndromes. The identification of miR-145-5p and miR-27b-3p as pivotal regulators of adipogenesis may catalyze the development of microRNA-based therapeutics applicable to conditions where adipocyte differentiation and function are perturbed, highlighting the wider relevance of this investigation.

This comprehensive miRNA profiling study leverages state-of-the-art molecular biology techniques, including next-generation sequencing and functional inhibition assays, to map the regulatory networks that underlie adipogenic failure in HGPS. Such technical rigor strengthens the impact of the findings and promises to inspire subsequent research designed to translate these molecular insights into clinical reality.

Importantly, the research team emphasizes that while targeting miR-145-5p and miR-27b-3p offers a tantalizing therapeutic angle, challenges remain in delivering microRNA inhibitors effectively in vivo, ensuring tissue specificity, and circumventing off-target effects. Nonetheless, these hurdles are increasingly surmountable with advances in nanoparticle delivery systems and gene therapy vectors, providing optimism for clinical application in the near future.

In summary, the work by Fenzl and colleagues represents a significant advance in understanding the molecular etiology of lipodystrophy in Hutchinson-Gilford progeria syndrome. By delineating how deregulated microRNAs disrupt adipogenic pathways, this study not only enhances biological understanding of premature aging disorders but also propels the field toward novel treatments that could alleviate fat tissue loss and improve patient outcomes.

The discovery that miR-145-5p and miR-27b-3p serve as key impediments to adipogenesis creates an essential framework for developing microRNA-targeted therapies. Such strategies might one day restore adipose tissue function, counter metabolic deficits, and extend healthspan in children afflicted with HGPS and potentially other metabolic diseases.

Subject of Research: Cells

Article Title: Deregulated miR-145 and miR-27b in Hutchinson-Gilford progeria syndrome: implications for adipogenesis

News Publication Date: 27-Aug-2025

Web References: Aging-US Volume 17, Issue 9

References: The study integrates findings from multiple referenced works, specifically literature sources numbered 73 to 80 in the original paper.

Image Credits: Copyright © 2025 Fenzl et al. Distributed under Creative Commons Attribution License (CC BY 4.0)

Keywords: aging, Hutchinson-Gilford progeria syndrome (HGPS), progerin, microRNAs, adipogenesis